Orphan Medical Devices in the European Union
Regulatory Q&As for Researchers
The OrphaDev4Kids Project offers regulatory support to stakeholders developing Orphan Medical Devices. We have compiled a series of Regulatory Q&As to help you in your medical device research and development.
In this section you can find information about Strategic Considerations for Researchers.
.If you need any additional information don’t hesitate to reach out to [email protected]
What key challenges should researchers consider when developing orphan medical devices?
Developing medical devices for rare diseases presents specific challenges due to the limited size and heterogeneity of patient populations. These challenges may affect:
- The design of clinical investigations;
- The availability of clinical data;
- The selection of appropriate clinical endpoints;
- The generation of robust evidence on safety and performance.
Researchers should therefore carefully plan the clinical development strategy, taking into account the proportional approach to clinical evidence recognised in MDCG 2024-10.
How can researchers design clinical studies for very small patient populations?
When patient populations are very limited, traditional clinical trial designs may not always be feasible. Researchers may consider alternative approaches, such as:
- Multicentre or multinational studies to increase recruitment;
- Adaptive or flexible study designs;
- Registry-based studies;
- The use of historical controls or real-world data.
These approaches should be scientifically justified and aligned with the requirements of the EU Medical Device Regulation (MDR) 2017/745 or the In Vitro Diagnostic Regulation (IVDR) 2017/746, where applicable.
Which role can multidisciplinary collaboration play in orphan device development?
Multidisciplinary collaboration plays a critical, often foundational, role in orphan device development by bringing together diverse expertise to overcome the high technical, financial, and regulatory barriers associated with small patient populations.
Establishing collaborative networks among various stakeholders can help optimize the medical device development process and accelerate the delivery of new therapies to patients.
Developing devices for rare diseases often requires collaboration between:
- Clinicians and professional users;
- Engineers and device developers;
- Regulatory experts;
- Patient organisations.
Such multidisciplinary collaboration is essential to move from concept to patient access and can help ensure that the device addresses real clinical needs, while also meeting regulatory and evidence requirements.
Why should regulatory considerations be integrated early in academic research?
Many orphan medical devices originate from academic or hospital-based research projects. However, if regulatory requirements are not considered, it may become difficult to later generate the evidence required for CE marking. Integrating regulatory considerations early in academic research is critical to ensure that scientific discoveries can effectively translate into real-world applications, such as new therapies or medical devices.
Integrating regulatory considerations early can help ensuring that:
- The clinical study design supports regulatory requirements;
- The data generated are suitable for clinical evaluation;
- The development pathway towards CE marking remains feasible.
Proactive planning aligns research with safety and quality standards and enhances the likelihood of successful commercialization or clinical adoption.